251280 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
AngioLab, Inc. engages in the development, manufacture, and distribution of pharmaceutical products. Its products include treatment for wet macular degeneration, nonalcoholic fatty liver disease treatment, periodontal disease treatment, treatment of otitis media with effusion, injection dermatitis remedy, antibody therapy, and foods that reduce visceral fat. The company was founded by Min-Yeong Kim on June 3, 1999 and is headquartered in Daejeon, South Korea.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
251280 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company